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Abstract Copy number variation is common in the human
genome with many regions, overlapping thousands of genes,
now known to be deleted or amplified. Aneuploidies and
other forms of chromosomal imbalance have a wide range of
adverse phenotypes and are a common cause of birth defects
resulting in significant morbidity and mortality. ‘‘Normal’’
copy number variants (CNVs) embedded within the regions
of chromosome imbalance may affect the clinical outcomes
by altering the local copy number of important genes or
regulatory regions: this could alleviate or exacerbate certain
phenotypes. In this way CNVs may contribute to the clinical
variability seen in many disorders caused by chromosomal
abnormalities, such as the congenital heart defects (CHD)
seen in *40% of Down’s syndrome (DS) patients. Inves-
tigation of CNVs may therefore help to pinpoint critical
genes or regulatory elements, elucidating the molecular
mechanisms underlying these conditions, also shedding
light on the aetiology of such phenotypes in people without
major chromosome imbalances, and ultimately leading to
their improved detection and treatment.
Keywords Copy number variation  Chromosomal
abnormalities  Aneuploidy  Phenotypic variability
Introduction
One of the fastest-growing research areas in genetics in the
past few years has been the investigation of structural
variation in the human genome, with copy number variants
(CNVs) found to be much more common than previously
imagined. As well as contributing to interindividual phe-
notypic variation in the general population, these genomic
variants may hold the key to understanding the differences
in severity seen in people with chromosomal abnormalities.
Aneuploidy, for example, can be regarded as a state of
large-scale changed copy number resulting from loss or
gain of an entire chromosome, arising due to non-dis-
junction during cell division in either meiosis I or II. An-
euploidies and other chromosomal abnormalities are a
common cause of birth defects and are associated with
significant morbidity and mortality. The spectrum of phe-
notypes seen in each affected individual is clearly depen-
dant on the particular chromosomal region concerned,
although there is still a great deal of variability in the
presentation of phenotypes.
Individuals with Down’s syndrome (DS), for example,
like those with other aneuploidies or with chromosomal
deletions or duplications, vary greatly in their clinical
features, capabilities, disabilities and prognosis. Although
many of these people, with the necessary social and clinical
support, can and do lead active and fulfilling lives, some
DS sub-phenotypes are associated with increased morbidity
and mortality in infancy. Congenital heart defects (CHD),
for example, occur in *40% of DS; 50% of these require
surgical correction within the first year of life and survival
to one year is only *76% compared with *91% for non-
CHD DS patients (Yang et al. 2002). An appreciation of
the molecular mechanisms behind this phenotypic variation
and the identification of susceptibility loci may provide
diagnostic and prognostic markers to enable us to predict
the occurrence of clinically serious phenotypes, such as
CHD, in DS. Additionally, analysis of these loci might help
elucidate the mechanisms of CHD in non-DS children.
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Copy number variation and its effects on human
phenotype
To assess the implications of genomic copy number vari-
ants in the context of chromosomal abnormalities, it is
helpful to consider the evidence that they affect phenotype
in euploid individuals. Until recently, it was assumed that
there are two copies of every gene in euploid individuals,
with one on the maternally-inherited chromosome and the
other inherited paternally. Any two human genomes were
thought to be 99.9% similar, with the main source of
genetic variation due to single nucleotide polymorphisms
(SNPs). Technological advances often result in paradigm
shifts, however, and an unexpected amount of copy number
variation was revealed through the advent of array com-
parative genomic hybridisation (array CGH) and, more
recently, of second-generation sequencing technologies.
There are currently over 14,000 CNV regions listed on the
TCAG Database of Genomic Variants (DGV, updated
March 2010), predicted to overlap a significant proportion
of the genome. Approximately 11,500 genes, including
over 2600 listed in the Online Mendelian Inheritance in
Man database, are reportedly overlapped by CNVs (DGV
March 2010).
To understand the role of CNVs in human disease, it is
important to consider how these genomic variants may
affect phenotype. Deletion or duplication of dosage-sensi-
tive genes, or their regulatory regions, could have adverse
phenotypic effects, and copy number changes correlate
with expression of affected genes (Henrichsen et al. 2009;
Stranger et al. 2007). The majority of common CNVs are
much smaller than the subset investigated by Stranger et al.
(2007), leading them to propose that a substantial propor-
tion of heritable variation in gene expression may be
explained by copy number variation. In addition to direct
copy number effects, CNVs may also exert positional
effects, for example by shifting them closer to or further
away from heterochromatin. Furthermore, adverse pheno-
typic effects may result from interactions between CNVs
and other variants, for example a deletion on one chro-
mosome may unmask a harmful recessive allele on the
other. Conversely, a genomic duplication that incorporates
a harmful mutation may have a double gain-of-function
effect: a duplication of the PRSS1 and PRSS2 genes along
with a missense mutation was recently shown to cause
hereditary pancreatitis (Masson et al. 2008).
It is likely, therefore, that CNVs do significantly affect
human phenotypes, and this is reflected by an increasing
number of associations reported between CNVs and disease
(Tables 1, 2). Several autoimmune disorders have been
associated with CNVs, including systemic lupus erythe-
matosus (Fanciulli et al. 2007), Crohn’s disease (Fellermann
et al. 2006; McCarroll et al. 2008) and psoriasis (Hollox
et al. 2008), and a range of other diseases have now been
associated with CNVs (reviewed in Zhang et al. 2009). It has
been postulated that CNVs could account for a large pro-
portion of the missing heritability of common diseases that
has emerged after the recent plethora of genome-wide
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1q23 FCGR3B Low copy numbers (\2) Fanciulli et al. (2007)
6p21.3 C4 Low copy numbers (\3) Yang et al. (2007)
Crohn’s disease 8p23.1 Beta-Defensins Low copy numbers (\4) Fellermann et al. (2006)
5q33.1 IRGM Low copy numbers (\2) McCarroll et al. (2008)
Psoriasis 8p23.1 Beta-Defensins High copy numbers
([4)
Hollox et al. (2008)
Osteoporosis 4q13.2 UGT2B17 Presence of gene
([0 copies)
Yang et al. (2008)
Graft-vs.-host
disease (GVHD)
4q13.2 UGT2B17 Absence of gene
(0 copies)
McCarroll et al. (2009)
Neuroblastoma 1q21.1 Novel neuroblastoma
breakpoint family (NBPF)
gene
Low copy numbers (\2) Diskin et al. (2009)
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association studies (GWAS) (reviewed in Manolio et al.
2009), but this is the subject of heated controversy. In a
recent large-scale genotyping survey of common CNVs,
Conrad et al. (2010) found that the CNVs that they were able
to genotype easily were only in linkage disequilibrium with
34 out of 1,554 trait-associated SNPs from GWAS, thus they
suggest that common CNVs are unlikely to account for
much of the missing heritability. There is, however, a par-
ticular challenge in analysis of amplified sequences (which
may be remote from the original sequence copy (Conrad
et al. 2010)), multi-allelic variants (particularly VNTRs) and
recurrent events, so further analysis of those CNV types is
required before the full contribution of common CNVs to
human disease can be assessed.
As an alternative to the common disease-common
variants hypothesis (Chakravarti 1999; Lander 1996), the
rare variants hypothesis postulates that a collection of
many, individually less frequent copy number changes may
collectively significantly contribute to disease susceptibil-
ity. Although many CNVs are present in an appreciable
proportion of the population, the majority are likely to be
less frequent: for example, in our array CGH investigation
of 50 apparently healthy French male samples, 809 out of
1469 (*55%) multi-probe CNV regions were identified in
only one individual (de Smith et al. 2007). Rare copy
number changes have been implicated in neurodevelop-
mental disorders, including autism (Marshall et al. 2008;
Sebat et al. 2007) and schizophrenia (Wilson et al. 2006;
Xu et al. 2008). Furthermore, a number of rare genomic
structural variants have recently been associated with
obesity (Bochukova et al. 2010; Walters et al. 2010), and
many more low frequency CNVs with strong effects may
contribute to common disease phenotypes: large sample
cohorts and different populations will need to be investi-
gated to uncover these rare variants.
CNVs in aneuploidy
Thus, it is now clear that genomic structural variants may
significantly impact phenotype in euploid individuals:
these effects may be even more pronounced in people with
chromosomal abnormalities. For example, a phenotype
associated with a particular monosomy or sub-chromo-
somal deletion may be ameliorated by the presence of an
amplification CNV on the unaffected chromosome, as gene
expression within the CNV region could remain at a nor-
mal, euploid level. Conversely, a deletion CNV could
cause a more severe phenotype.
An example could be Turner syndrome, which is the
only whole chromosome monosomy (45, X) that is viable
in humans, with approximately 1 in 2,000 female births
having one copy of the X chromosome (Nielsen and Wo-
hlert 1990). In addition to the main features of short stature
and ovarian failure, present in almost all cases, there are
many other phenotypes that may present, including a short
webbed neck, kidney malformations, hearing problems and
various learning difficulties, as well as increased risk of
type 1 diabetes (Gravholt et al. 1998). It is possible that the
extensive copy number variation on the X chromosome—
37.8% according to the DGV (March 2010)—may con-
tribute to phenotypic variability in this disorder. For
example, a critical region for the neurocognitive deficits in
Turner syndrome was mapped to Xp22.3, containing 31
genes (Ross et al. 2000), and several CNV loci have been
reported in this region.
Similarly, phenotypic variation in genomic disorders
could also be a reflection of underlying copy number var-
iation within the relevant genomic region. The most com-
mon microdeletion in humans is DiGeorge syndrome (or
velo-cardio-facial syndrome) caused by deletion of a
1.5–3 Mb region at chromosome 22q11.2 (Scambler et al.






Parkinson’s disease 4q22.1 SNCA Triplication (4 copies) Singleton et al. (2003)
Autosomal dominant early-onset
Alzheimer’s Disease
21q21 APP Duplication (3 copies) Rovelet-Lecrux et al. (2006)
Hereditary pancreatitis 7q34 PRSS1 and
PRSS2
Triplication (4 copies) Le Marechal et al. (2006)
Autism Multiple Multiple Deletions and duplications Sebat et al. (2007) and Glessner
et al. (2009)
Bipolar disorder 3q13.3 GSK3b Duplication Lachman et al. (2007)
Schizophrenia Multiple Multiple Deletions and duplications Xu et al. (2008) and Walsh et al.
(2008)
Tetralogy of fallot Multiple Multiple Deletions and duplications Greenway et al. (2009)
Obesity Multiple Multiple Deletions and duplications Bochukova et al. (2010)
16p11.2 Multiple Deletion Walter et al. (2010)
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1992) and occurring in 1 in 5,000 births (Botto et al. 2003).
This disorder is also associated with variable phenotypes,
such as cleft palate, congenital heart disease (Shprintzen
et al. 1978), renal anomalies (Czarnecki et al. 1998) and
increased risk of schizophrenia (Murphy et al. 1999).
Several CNV loci have been identified within the 22q11.2
deletion region in apparently healthy individuals: of
interest, two of the candidate genes for the schizophrenia
phenotype, PRODH (Li et al. 2004) and GNB1L (Williams
et al. 2008), are overlapped by a number of CNVs, and
these could potentially modify this phenotype in DiGeorge
patients.
In polyploidy or sub-chromosomal duplications where
abnormalities result from extra copies of the chromosome
regions, deletion CNVs may ‘‘normalise’’ copy number.
Alternatively, there is potential for even greater amplifi-
cation of copy number where amplification CNVs are
present. A simple duplication CNV on the non-disjoining
chromosome may lead to the presence of up to six copies of
a gene in a trisomic individual (Fig. 1) and the subsequent
phenotypic effects associated with increased gene expres-
sion levels. Conversely, a gene deletion on the non-
disjoining chromosome may alleviate the expected effect
of trisomy by reducing the local copy number state to one
or two copies. Thus, the compounded effect of aneuploidy
and copy number variation has the potential to generate a
much wider range of phenotypes than would be expected
on the basis of chromosome number alone. It has been
suggested, therefore, that CNVs are likely to act as ‘mod-
ifiers of the phenotypic variability of trisomies’ (Beckmann
et al. 2007) and the same is probably also true for smaller
chromosomal imbalances.
Phenotypic variability in Down’s syndrome
may be modified by CNVs
Using Down’s Syndrome as an example, an extra copy of
chromosome 21 is not sufficient to cause the full range of
phenotypes associated with this disorder, as individuals can
present with a range of sub-phenotypes. Some features are
almost always present, such as the characteristic facial
appearance and mental retardation, although these can vary

















Fig. 1 Mechanisms of
phenotypic variability in
trisomy resulting from copy
number variation. Amplification
of gene copy number during
non-disjunction (NDJ) can
result in a range of copy number
states. Where dosage-sensitive
genes are involved, this may
result in a wide range of
associated phenotypes. This
figure illustrates a number of
different potential outcomes for
a single gene which is
susceptible to duplication and/or
deletion. a illustrates the
difference between meiosis I
(MI) and meiosis II (MII) NDJ
occurring in parent A;
b–d illustrate just three of the
possible scenarios resulting
from NDJ in parent A if gene
duplications are present in one
or both parents, each of which
could result in over-expression
of a dosage-sensitive gene;
e illustrates how a deletion on
parent B and MII NDJ in parent
A, however, that leads to a total
of two copies of the gene in the
trisomic child which could
potentially ameliorate the
pathological effects of trisomy
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1996). Other features, however, are only present in a
fraction of DS cases: for example, congenital heart defects
(CHD) are present in *40% of cases (Park et al. 1977) and
gastrointestinal (GI) defects in *8% of DS (Epstein et al.
1991). Leukaemia is also common in DS, with an *20%
increased risk of acute lymphoblastic leukaemia (ALL)
(Hasle et al. 2000), and transient myeloproliferative dis-
order occurring in *10% of DS newborns, of which
10–20% develop acute megakaryoblastic leukaemia
(AMKL) before the age of 4 (reviewed in Hasle 2001). A
detailed knowledge of the genes on the affected chromo-
some is required to understand the phenotypic effects of
aneuploidy. In addition, it is important to determine the
overall effects of gene dosage imbalance, which may also
be complex.
Individuals with partial trisomy 21 resulting from
unbalanced chromosomal translocations will only exhibit
those features associated with the extra genomic material
present. Molecular analysis of these patients enables
‘phenotypic mapping’ by defining the critical genomic
regions that harbour genes associated with various pheno-
types (Epstein et al. 1991). As with all regions of the
genome, many common CNVs and rarer genomic struc-
tural variants are found on chromosome 21. Two recent
reports describe structural variations in which the presence
of increased copies of genomic regions on chromosome 21
contributes to human phenotype. In one study, duplication
of a region at 21q21 that included the amyloid precursor
protein (APP) gene was found to cause familial Alzhei-
mer’s disease in five separate families (Rovelet-Lecrux
et al. 2006). The duplication varied in size from 0.58 to
6.37 Mb and contained from 5 to 12 annotated genes
including APP. Despite the largest of these duplications
being over 6 Mb, none of the families exhibited any clin-
ical evidence of DS (Cabrejo et al. 2006). A second
duplication of a 4.3 Mb region at 21q22.13-q22.2,
containing just over 30 genes, did help refine the map of
the DS critical region (DCR) as it caused a DS phenotype
in three family members (Ronan et al. 2007). These indi-
viduals had the facial characteristics of DS and mild cog-
nitive disability indicating that this region includes part of
the DCR but not all of it. It is apparent, therefore, that
different sub-phenotypes of trisomy 21 are caused by
increased copy number at different regions across chro-
mosome 21. It is also evident that some DS individuals
who are trisomic for a particular critical region do not
always exhibit the associated phenotype, or display a much
milder form.
A complex interplay of molecular factors is likely to be
responsible for the trisomic phenotypes, possibly involving
non-chromosome 21 genes. Furthermore, interaction of
trisomy with the presence of certain embedded deleterious
alleles or haplotypes may contribute to the variable pre-
sentation of the different phenotypes (including degree of
mental retardation, congenital heart defects, Hirschprung
and other gut diseases, and leukaemia). The increasing
amount of copy number variation that has been discovered
in the human genome, specifically on chromosome 21,
adds another dimension to the molecular consequences of
trisomy: it is possible that the phenotypic variability seen in
DS may be due to CNVs on this chromosome.
On the DGV, there are 507 reported CNV calls covering
35.0% of chromosome 21, which is similar to the CNV
coverage of other chromosomes (33.9%) (DGV March
2010). Many of these are common in the population. For
example, our investigation of only 50 healthy French male
samples revealed 20 multi-probe CNVs, and an additional
57 single probe CNV signals, on chromosome 21 (de Smith
et al. 2007): almost half were detected in multiple samples
(47%), and 34% had a frequency of [5% (Fig. 2). In
addition, these CNVs overlapped 38 known genes. There













q21.1 q21.3 q22.12 q22.2
Fig. 2 Copy number variation on chromosome 21. This shows the
penetrance plot of aberration calls on chromosome 21 from array
CGH data from 50 apparently healthy French Caucasian males (de
Smith et al. 2007), generated using ADM-2 algorithm with threshold
4 in CGH Analytics 3.4. This displays the percentage of the 50 arrays
that have an aberration at each probe position along the chromosome:
deletion aberrations point downwards from 0, and amplifications
point upwards. The box shows the position of the CNV within
DSCAM
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and metastasis-inducing protein 1), for example, which is
expressed in almost all analysed tumour cell lines,
including B- and T-lymphomas, melanomas and carcino-
mas (Habets et al. 1995). A CNV was also found within
DSCAM¸ which is a good candidate gene for the CHD
phenotype seen in DS, as it lies within the predicted min-
imum critical region and is expressed in the heart during
cardiac development (Korbel et al. 2009). Several other
CNVs have since been discovered in this gene, as listed on
the DGV, including a common deletion that incorporates 4
exons (Matsuzaki et al. 2009).
Other genes within the CHD critical region also overlap
CNVs: a common intronic deletion (10%) was identified in
C2CD2 (Conrad et al. 2010); 6 CNVs have been reported
within PRDM15, including one deletion overlapping 5 exons
that was found in 3/90 Yoruban individuals (Matsuzaki et al.
2009); and one deletion was identified in BACE2 overlap-
ping the last exon of this gene (Mills et al. 2006).
CNVs also overlap RUNX1, with one deletion removing
the promoter region and first exon of this gene (Gusev et al.
2009). RUNX1 codes for a transcription factor involved in
haematopoiesis (North et al. 2002) and is associated with
AMKL, which is estimated to be 500-fold more frequent in
children with DS than in the general population (reviewed
in Zipursky et al. 1992): CNVs in this gene may, therefore,
protect against or increase susceptibility to leukaemia in
DS. These CNV loci and other regions that could poten-
tially impact variable phenotypes of trisomy 21 are listed in
Table 3.
Analysis of copy number variation on chromosome 21
may, therefore, lead to a better understanding of the eti-
ology of DS sub-phenotypes and could possibly shed light
on the origin of these conditions in the wider non-trisomic
population. Knowledge of which genes are involved in the
generation of CHD in DS, for example, and how they
interact with other gene products, could have many
implications for managing CHD in the non-trisomic pop-
ulation: for example, adult onset CHD may be prevented
by therapeutic agents that target critical pathways con-
trolling cardiogenesis, and new approaches may be devel-
oped for stem-cell guided cardiac repair (reviewed in
Passier et al. 2008).
Since the discovery of trisomy 21, it has been hypoth-
esised that genes present in three copies are over-expressed












26,173,965–26,174,696 APP Alzheimer’s disease No Gain 1/1 McKernan et al. (2009)
26,196,591–26,196,901 No Loss 1/1 Wang et al. (2008)
31,337,700–31,424,326 TIAM1 Associated with
several different
cancers




Exon 1 Loss 6/2906 Gusev et al. (2009)
36,748,886–36,783,426 CLDN14 Hearing loss Exons 1–3 Loss/Gain Loss 1/50 de Smith et al. (2007)
Gain 1/50
36,785,973–36,801,336 No Loss/Gain Loss 6/90 Matsuzaki et al. (2009)
Gain 6/90
34,648,096–34,829,283 KCNE1 Down syndrome
critical region
(DCR)
All exons of KCNE1,
KCNE2, FAM165B,
and exons 2–4 of RCAN1




37,092,300–37,354,491 DSCR6 DCR All exons of DSCR6
and exons 1–7 of HLCS
Gain 1/776 Pinto et al. (2007)
HLCS
37,489,474–37,490,172 TTC3 DCR Exon 41 Gain 1/1 Kim et al. (2009)
40,466,951–40,489,050 DSCAM Congenital heart
defects (CHD)
Exons 12–15 Loss 9/90 Matsuzaki et al. (2009)
40,592,263–40,596,079 No Loss 1/40 Conrad et al. (2010)
41,568,947–41,572,987 BACE2 CHD Exon 9 Loss 1/36 Mills et al. (2006)
42,123,984–42,136,309 PRDM15 CHD Exons 14–18 Loss 3/90 Matsuzaki et al. (2009)
42,223,189–42,226,495 C2CD2 CHD No Loss 45/450 Conrad et al. (2010)
46,234,806–46,234,806 COL6A1 CHD No Gain 1/1 Levy et al. (2007)
46,367,207–46,399,800 COL6A2 CHD Exons 21–28 Gain 2/2026 Shaikh et al. (2009)
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by 1.5-fold relative to the euploid state, but this has sub-
sequently been shown to not always be the case. Some
genes are over expressed, some are expressed at euploid
levels while other genes appear to be down-regulated (Li
et al. 2006; Prandini et al. 2007). This may, of course,
reflect adaptive regulatory control, but may also reflect the
effects of local copy number variation on chromosome 21,
which will result in deviations from the predicted three
copies of each gene, as shown in Fig. 1.
Conclusions
Copy number variation may, therefore, make a significant
contribution to phenotypic variation in aneuploidy and
other chromosomal abnormalities. Targeted analysis of
such variation might, therefore, represent an effective
strategy for refining critical regions and pinpointing genes
central to key pathways (i.e. of cardiogenesis or oncogen-
esis). This would also help to enable the prediction of
which individuals may develop serious phenotypes, such as
CHD in DS, which may add an extra dimension to ante-
natal screening programmes in the future by contributing to
the process of ‘informed choice’ by the potential parents of
a DS child, as well as well as aiding the long term man-
agement of these patients. Additional benefits may also
accrue from increased understanding of pathogenic mech-
anisms relevant to patients with similar phenotypes outside
the context of chromosomal imbalance.
In summary, recent technological advances, such as
high-resolution array CGH and second-generation
sequencing, have vastly and rapidly increased our knowl-
edge of copy number variation in the human genome. As
these techniques continue to improve, and greater numbers
of samples and populations are investigated, so our
understanding of how copy number correlates with phe-
notype will grow, yielding information not just relevant to
individuals with chromosomal imbalances, but to similar
conditions in the wider population.
References
Aitman TJ, Dong R, Vyse TJ, Norsworthy PJ, Johnson MD, Smith J,
Mangion J, Roberton-Lowe C, Marshall AJ, Petretto E et al
(2006) Copy number polymorphism in Fcgr3 predisposes to
glomerulonephritis in rats and humans. Nature 439:851–855
Beckmann JS, Estivill X, Antonarakis SE (2007) Copy number
variants and genetic traits: closer to the resolution of phenotypic
to genotypic variability. Nat Rev Genet 8:639–646
Bochukova EG, Huang N, Keogh J, Henning E, Purmann C,
Blaszczyk K, Saeed S, Hamilton-Shield J, Clayton-Smith J,
O’Rahilly S et al (2010) Large, rare chromosomal deletions
associated with severe early-onset obesity. Nature 463:666–670
Botto LD, May K, Fernhoff PM, Correa A, Coleman K, Rasmussen
SA, Merritt RK, O’Leary LA, Wong LY, Elixson EM et al
(2003) A population-based study of the 22q11.2 deletion:
phenotype, incidence, and contribution to major birth defects
in the population. Pediatrics 112:101–107
Cabrejo L, Guyant-Marechal L, Laquerriere A, Vercelletto M, De la
Fourniere F, Thomas-Anterion C, Verny C, Letournel F,
Pasquier F, Vital A et al (2006) Phenotype associated with
APP duplication in five families. Brain 129:2966–2976
Chakravarti A (1999) Population genetics–making sense out of
sequence. Nat Genet 21:56–60
Conrad DF, Pinto D, Redon R, Feuk L, Gokcumen O, Zhang Y, Aerts
J, Andrews TD, Barnes C, Campbell P et al (2010) Origins and
functional impact of copy number variation in the human
genome. Nature 464:704–712
Czarnecki PM, Van Dyke DL, Vats S, Feldman GL (1998) A mother
with VCFS and unilateral dysplastic kidney and her fetus with
multicystic dysplastic kidneys: additional evidence to support
the association of renal malformations and VCFS. J Med Genet
35:348
Database of Genomic Variants—a curated catalogue of structural
variation in the human genome. http://projects.tcag.ca/variation/
de Smith AJ, Tsalenko A, Sampas N, Scheffer A, Yamada NA, Tsang
P, Ben-Dor A, Yakhini Z, Ellis RJ, Bruhn L et al (2007) Array
CGH analysis of copy number variation identifies 1284 new
genes variant in healthy white males: implications for associa-
tion studies of complex diseases. Hum Mol Genet 16:2783–2794
Diskin SJ, Hou C, Glessner JT, Attiyeh EF, Laudenslager M, Bosse
K, Cole K, Mosse YP, Wood A, Lynch JE et al (2009) Copy
number variation at 1q21.1 associated with neuroblastoma.
Nature 459:987–991
Epstein CJ, Korenberg JR, Anneren G, Antonarakis SE, Ayme S,
Courchesne E, Epstein LB, Fowler A, Groner Y, Huret JL et al
(1991) Protocols to establish genotype-phenotype correlations in
Down syndrome. Am J Hum Genet 49:207–235
Fanciulli M, Norsworthy PJ, Petretto E, Dong R, Harper L, Kamesh
L, Heward JM, Gough SC, de Smith A, Blakemore AI et al
(2007) FCGR3B copy number variation is associated with
susceptibility to systemic, but not organ-specific, autoimmunity.
Nat Genet 39:721–723
Fellermann K, Stange DE, Schaeffeler E, Schmalzl H, Wehkamp J,
Bevins CL, Reinisch W, Teml A, Schwab M, Lichter P et al
(2006) A chromosome 8 gene-cluster polymorphism with low
human beta-defensin 2 gene copy number predisposes to Crohn
disease of the colon. Am J Hum Genet 79:439–448
Glessner JT, Wang K, Cai G, Korvatska O, Kim CE, Wood S, Zhang
H, Estes A, Brune CW, Bradfield JP et al (2009) Autism
genome-wide copy number variation reveals ubiquitin and
neuronal genes. Nature 459:569–573
Gonzalez E, Kulkarni H, Bolivar H, Mangano A, Sanchez R, Catano G,
Nibbs RJ, Freedman BI, Quinones MP, Bamshad MJ et al (2005)
The influence of CCL3L1 gene-containing segmental duplications
on HIV-1/AIDS susceptibility. Science 307:1434–1440
Gravholt CH, Juul S, Naeraa RW, Hansen J (1998) Morbidity in
Turner syndrome. J Clin Epidemiol 51:147–158
Greenway SC, Pereira AC, Lin JC, DePalma SR, Israel SJ, Mesquita
SM, Ergul E, Conta JH, Korn JM, McCarroll SA et al (2009) De
novo copy number variants identify new genes and loci in
isolated sporadic tetralogy of Fallot. Nat Genet 41:931–935
Gusev A, Lowe JK, Stoffel M, Daly MJ, Altshuler D, Breslow JL,
Friedman JM, Pe’er I (2009) Whole population, genome-wide
mapping of hidden relatedness. Genome Res 19:318–326
Habets GG, van der Kammen R, Stam JC, Michiels F, Collard JG
(1995) Sequence of the human invasion-inducing TIAM1 gene,
its conservation in evolution and its expression in tumor cell
lines of different tissue origin. Oncogene 10:1371–1376
HUGO J (2010) 4:1–9 7
123
Hasle H (2001) Pattern of malignant disorders in individuals with
Down’s syndrome. Lancet Oncol 2:429–436
Hasle H, Clemmensen IH, Mikkelsen M (2000) Risks of leukaemia
and solid tumours in individuals with Down’s syndrome. Lancet
355:165–169
Henrichsen CN, Vinckenbosch N, Zollner S, Chaignat E, Pradervand
S, Schutz F, Ruedi M, Kaessmann H, Reymond A (2009)
Segmental copy number variation shapes tissue transcriptomes.
Nat Genet 41:424–429
Hollox EJ, Huffmeier U, Zeeuwen PL, Palla R, Lascorz J, Rodijk-
Olthuis D, van de Kerkhof PC, Traupe H, de Jongh G, den Heijer
M et al (2008) Psoriasis is associated with increased beta-
defensin genomic copy number. Nat Genet 40:23–25
Kallen B, Mastroiacovo P, Robert E (1996) Major congenital
malformations in Down syndrome. Am J Med Genet 65:160–166
Kim JI, Ju YS, Park H, Kim S, Lee S, Yi JH, Mudge J, Miller NA,
Hong D, Bell CJ et al (2009) A highly annotated whole-genome
sequence of a Korean individual. Nature 460:1011–1015
Korbel JO, Tirosh-Wagner T, Urban AE, Chen XN, Kasowski M, Dai
L, Grubert F, Erdman C, Gao MC, Lange K et al (2009) The
genetic architecture of Down syndrome phenotypes revealed by
high-resolution analysis of human segmental trisomies. Proc
Natl Acad Sci USA 106:12031–12036
Lachman HM, Pedrosa E, Petruolo OA, Cockerham M, Papolos A,
Novak T, Papolos DF, Stopkova P (2007) Increase in GSK3beta
gene copy number variation in bipolar disorder. Am J Med Genet
B Neuropsychiatr Genet 144B:259–265
Lander ES (1996) The new genomics: global views of biology.
Science 274:536–539
Le Marechal C, Masson E, Chen JM, Morel F, Ruszniewski P, Levy
P, Ferec C (2006) Hereditary pancreatitis caused by triplication
of the trypsinogen locus. Nat Genet 38:1372–1374
Levy S, Sutton G, Ng PC, Feuk L, Halpern AL, Walenz BP, Axelrod
N, Huang J, Kirkness EF, Denisov G et al (2007) The diploid
genome sequence of an individual human. PLoS Biol 5:e254
Li T, Ma X, Sham PC, Sun X, Hu X, Wang Q, Meng H, Deng W, Liu
X, Murray RM et al (2004) Evidence for association between
novel polymorphisms in the PRODH gene and schizophrenia in a
Chinese population. Am J Med Genet B Neuropsychiatr Genet
129B:13–15
Li CM, Guo M, Salas M, Schupf N, Silverman W, Zigman WB,
Husain S, Warburton D, Thaker H, Tycko B (2006) Cell type-
specific over-expression of chromosome 21 genes in fibroblasts
and fetal hearts with trisomy 21. BMC Med Genet 7:24
Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter
DJ, McCarthy MI, Ramos EM, Cardon LR, Chakravarti A et al
(2009) Finding the missing heritability of complex diseases.
Nature 461:747–753
Marshall CR, Noor A, Vincent JB, Lionel AC, Feuk L, Skaug J,
Shago M, Moessner R, Pinto D, Ren Y et al (2008) Structural
variation of chromosomes in autism spectrum disorder. Am J
Hum Genet 82:477–488
Masson E, Le Marechal C, Delcenserie R, Chen JM, Ferec C (2008)
Hereditary pancreatitis caused by a double gain-of-function
trypsinogen mutation. Hum Genet 123:521–529
Matsuzaki H, Wang H, Hu J, Rava R, Fu GK (2009) High resolution
discovery and confirmation of copy number variants in 90
Yoruba Nigerians. Genome Biol 10:R125
McCarroll SA, Huett A, Kuballa P, Chilewski SD, Landry A, Goyette
P, Zody MC, Hall JL, Brant SR, Cho JH et al (2008) Deletion
polymorphism upstream of IRGM associated with altered IRGM
expression and Crohn’s disease. Nat Genet 40:1107–1112
McCarroll SA, Bradner JE, Turpeinen H, Volin L, Martin PJ,
Chilewski SD, Antin JH, Lee SJ, Ruutu T, Storer B et al (2009)
Donor-recipient mismatch for common gene deletion polymor-
phisms in graft-versus-host disease. Nat Genet 41:1341–1344
McKernan KJ, Peckham HE, Costa GL, McLaughlin SF, Fu Y, Tsung
EF, Clouser CR, Duncan C, Ichikawa JK, Lee CC et al (2009)
Sequence and structural variation in a human genome uncovered
by short-read, massively parallel ligation sequencing using two-
base encoding. Genome Res 19:1527–1541
Mills RE, Luttig CT, Larkins CE, Beauchamp A, Tsui C, Pittard WS,
Devine SE (2006) An initial map of insertion and deletion
(INDEL) variation in the human genome. Genome Res 16:
1182–1190
Murphy KC, Jones LA, Owen MJ (1999) High rates of schizophrenia
in adults with velo-cardio-facial syndrome. Arch Gen Psychiatry
56:940–945
Nielsen J, Wohlert M (1990) Sex chromosome abnormalities found
among 34, 910 newborn children: results from a 13 year incidence
study in Arhus, Denmark. Birth Defects Orig Artic Ser 26:
209–223
North TE, de Bruijn MF, Stacy T, Talebian L, Lind E, Robin C,
Binder M, Dzierzak E, Speck NA (2002) Runx1 expression
marks long-term repopulating hematopoietic stem cells in the
midgestation mouse embryo. Immunity 16:661–672
Park SC, Mathews RA, Zuberbuhler JR, Rowe RD, Neches WH,
Lenox CC (1977) Down syndrome with congenital heart
malformation. Am J Dis Child 131:29–33
Passier R, van Laake LW, Mummery CL (2008) Stem-cell-based
therapy and lessons from the heart. Nature 453:322–329
Pinto D, Marshall C, Feuk L, Scherer SW (2007) Copy-number
variation in control population cohorts. Hum Mol Genet 16(Spec
No. 2):R168–R173
Prandini P, Deutsch S, Lyle R, Gagnebin M, Delucinge Vivier C,
Delorenzi M, Gehrig C, Descombes P, Sherman S, Dagna
Bricarelli F et al (2007) Natural gene-expression variation in
Down syndrome modulates the outcome of gene-dosage imbal-
ance. Am J Hum Genet 81:252–263
Ronan A, Fagan K, Christie L, Conroy J, Nowak NJ, Turner G (2007)
Familial 4.3 Mb duplication of 21q22 sheds new light on the
Down syndrome critical region. J Med Genet 44:448–451
Ross JL, Roeltgen D, Kushner H, Wei F, Zinn AR (2000) The Turner
syndrome-associated neurocognitive phenotype maps to distal
Xp. Am J Hum Genet 67:672–681
Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerriere A,
Vital A, Dumanchin C, Feuillette S, Brice A, Vercelletto M et al
(2006) APP locus duplication causes autosomal dominant early-
onset Alzheimer disease with cerebral amyloid angiopathy. Nat
Genet 38:24–26
Scambler PJ, Kelly D, Lindsay E, Williamson R, Goldberg R,
Shprintzen R, Wilson DI, Goodship JA, Cross IE, Burn J (1992)
Velo-cardio-facial syndrome associated with chromosome 22
deletions encompassing the DiGeorge locus. Lancet 339:
1138–1139
Sebat J, Lakshmi B, Malhotra D, Troge J, Lese-Martin C, Walsh T,
Yamrom B, Yoon S, Krasnitz A, Kendall J et al (2007) Strong
association of de novo copy number mutations with autism.
Science 316:445–449
Shaikh TH, Gai X, Perin JC, Glessner JT, Xie H, Murphy K, O’Hara
R, Casalunovo T, Conlin LK, D’Arcy M et al (2009) High-
resolution mapping and analysis of copy number variations in
the human genome: a data resource for clinical and research
applications. Genome Res 19:1682–1690
Shprintzen RJ, Goldberg RB, Lewin ML, Sidoti EJ, Berkman MD,
Argamaso RV, Young D (1978) A new syndrome involving cleft
palate, cardiac anomalies, typical facies, and learning disabili-
ties: velo-cardio-facial syndrome. Cleft Palate J 15:56–62
Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus
J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R et al (2003)
alpha-Synuclein locus triplication causes Parkinson’s disease.
Science 302:841
8 HUGO J (2010) 4:1–9
123
Stranger BE, Forrest MS, Dunning M, Ingle CE, Beazley C, Thorne
N, Redon R, Bird CP, de Grassi A, Lee C et al (2007) Relative
impact of nucleotide and copy number variation on gene
expression phenotypes. Science 315:848–853
Walsh T, McClellan JM, McCarthy SE, Addington AM, Pierce SB,
Cooper GM, Nord AS, Kusenda M, Malhotra D, Bhandari A et al
(2008) Rare structural variants disrupt multiple genes in
neurodevelopmental pathways in schizophrenia. Science 320:
539–543
Walters RG, Jacquemont S, Valsesia A, de Smith AJ, Martinet D,
Andersson J, Falchi M, Chen F, Andrieux J, Lobbens S et al
(2010) A new highly penetrant form of obesity due to deletions
on chromosome 16p11.2. Nature 463:671–675
Wang J, Wang W, Li R, Li Y, Tian G, Goodman L, Fan W, Zhang J,
Li J, Guo Y et al (2008) The diploid genome sequence of an
Asian individual. Nature 456:60–65
Williams NM, Glaser B, Norton N, Williams H, Pierce T, Moskvina
V, Monks S, Del Favero J, Goossens D, Rujescu D et al (2008)
Strong evidence that GNB1L is associated with schizophrenia.
Hum Mol Genet 17:555–566
Wilson GM, Flibotte S, Chopra V, Melnyk BL, Honer WG, Holt RA
(2006) DNA copy-number analysis in bipolar disorder and
schizophrenia reveals aberrations in genes involved in glutamate
signaling. Hum Mol Genet 15:743–749
Xu B, Roos JL, Levy S, van Rensburg EJ, Gogos JA, Karayiorgou M
(2008) Strong association of de novo copy number mutations
with sporadic schizophrenia. Nat Genet 40:880–885
Yang Q, Rasmussen SA, Friedman JM (2002) Mortality associated
with Down’s syndrome in the USA from 1983 to 1997: a
population-based study. Lancet 359:1019–1025
Yang Y, Chung EK, Wu YL, Savelli SL, Nagaraja HN, Zhou B,
Hebert M, Jones KN, Shu Y, Kitzmiller K et al (2007) Gene
copy-number variation and associated polymorphisms of com-
plement component C4 in human systemic lupus erythematosus
(SLE): low copy number is a risk factor for and high copy
number is a protective factor against SLE susceptibility in
European Americans. Am J Hum Genet 80:1037–1054
Yang TL, Chen XD, Guo Y, Lei SF, Wang JT, Zhou Q, Pan F, Chen
Y, Zhang ZX, Dong SS et al (2008) Genome-wide copy-number-
variation study identified a susceptibility gene, UGT2B17, for
osteoporosis. Am J Hum Genet 83:663–674
Zhang F, Gu W, Hurles ME, Lupski JR (2009) Copy number variation
in human health, disease, and evolution. Annu Rev Genomics
Hum Genet 10:451–481
Zipursky A, Poon A, Doyle J (1992) Leukemia in Down syndrome: a
review. Pediatr Hematol Oncol 9:139–149
Zogopoulos G, Ha KC, Naqib F, Moore S, Kim H, Montpetit A,
Robidoux F, Laflamme P, Cotterchio M, Greenwood C et al
(2007) Germ-line DNA copy number variation frequencies in a
large North American population. Hum Genet 122:345–353
HUGO J (2010) 4:1–9 9
123
